Dolutegravir does not affect methadone pharmacokinetics in opioid-dependent, HIV-seronegative subjects

Drug and Alcohol Dependence

Volumn 133, Issue 2, 2013, Pages 781-784

  Song, Ivy ^a   Mark, Stephen ^b   Chen, Shuguang ^a   Savina, Paul ^a   Wajima, Toshihiro ^c   Peppercorn, Amanda ^a   Bala, Urmilla ^d   Geoffroy, Pierre ^d   Piscitelli, Stephen ^a  

^a GLAXOSMITHKLINE   (United States)

^b GLAXOSMITHKLINE   (Canada)

^c SHIONOGI AND CO LTD   (Japan)

^d SYNEOS HEALTH   (United States)

Author keywords

Dolutegravir; Drug interaction; Methadone; Pharmacokinetics

Indexed keywords

DOLUTEGRAVIR; METHADONE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; COMPARTMENT MODEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DRUG BLOOD LEVEL; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAM; FATIGUE; FEMALE; HEADACHE; HEMATURIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LABORATORY TEST; MALE; METHADONE TREATMENT; OPEN STUDY; OPIATE ADDICTION; PANIC; PHARMACODYNAMICS; PRIORITY JOURNAL; REPEATED DRUG DOSE; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VITAL SIGN;

DOLUTEGRAVIR; DRUG INTERACTION; METHADONE; PHARMACOKINETICS;

ADOLESCENT; ADULT; AGED; DRUG INTERACTIONS; FEMALE; HETEROCYCLIC COMPOUNDS, 3-RING; HIV INTEGRASE INHIBITORS; HIV SERONEGATIVITY; HUMANS; MALE; METHADONE; MIDDLE AGED; NARCOTICS; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; PUPIL; SUBSTANCE ABUSE, INTRAVENOUS; SUBSTANCE WITHDRAWAL SYNDROME; YOUNG ADULT;

EID: 84887018042     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2013.08.009     Document Type: Article

References (16)

1. Cao Y.-J., Smith P.F., Wire M.B., Lou Y., Lancaster C.T., Causon R.C., Bigelow G.E., Martinez E., Fuchs E.J., Radebaugh C., McCabe S., Hendrix C.W. Pharmacokinetics and pharmacodynamics of methadone enantiomers after coadministration with fosamprenavir-ritonavir in opioid-dependent subjects. Pharmacotherapy 2008, 28:863-874.
2. Crauwels H., van Heeswijk R., Vandevoorde A., McNeeley D., Buelens A., Boven K., Hoetelmans R. Pharmacokinetic Interaction Study Between TMC278, a Next-Generation NNRTI, and Methadone. Presented at the 11th International Workshop on Clinical Pharmacology of HIV Therapy 2010.
3. Dooley K.E., Sayre P., Borland J., Purdy E., Chen S., Song I., Peppercorn A., Everts S., Piscitelli S., Flexner C. Safety, tolerability, and pharmacokinetics of the HIV integrase inhibitor dolutegravir given twice daily with rifampin or once daily with rifabutin: results of a phase 1 study among healthy subjects. J. Acquir. Immune Defic. Syndr. 2013, 62:21-27.
4. Eap C.B., Buclin T., Baumann P. Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. Clin. Pharmacokinet. 2002, 41:1153-1193.
5. Eron J.J., Clotet B., Durant J., Katlama C., Kumar P., Lazzarin A., Poizot-Martin I., Richmond G., Soriano V., Ait-Khaled M., Fujiwara T., Huang J., Min S., Vavro C., Yeo J. Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING study. J. Infect. Dis. 2013, 207:740-748. for the VIKING Study Group.
6. Kharasch E.D., Walker A., Whittington D., Hoffer C., Bedynek P.S. Methadone metabolism and clearance are induced by nelfinavir despite inhibition of cytochrome P4503A (CYP3A) activity. Drug Alcohol Depend. 2009, 101:158-168.
7. Koteff J., Borland J., Chen S., Song I., Peppercorn A., Koshiba T., Cannon C., Muster H., Piscitelli S.C. A phase 1 study to evaluate the effect of dolutegravir on renal function via measurement of iohexol and para-aminohippurate clearance in healthy subjects. Br. J. Clin. Pharmacol. 2013, 75:990-996.
8. Lansky A., Brooks J.T., DiNenno E., Heffelfinger J., Hall H.I., Mermin J. Epidemiology of HIV in the United States. J. Acquir. Immune Defic. Syndr. 2010, 55(suppl. 2):S64-S68.
9. McCance-Katz E.F., Rainey P.M., Friedland G., Jatlow P. The protease inhibitor lopinavir-ritonavir may produce opiate withdrawal in methadone-maintained patients. Clin. Infect. Dis. 2003, 37:476-482.
10. Min S., Sloan L., DeJesus E., Hawkins T., McCurdy L., Song I., Stroder R., Chen S., Underwood M., Fujiwara T., Piscitelli S., Lalezari J. Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults. AIDS 2011, 25:1737-1745.
11. Raffi F., Rachlis A., Stellbrink H.-J., Hardy W.D., Torti C., Orkin C., Bloch M., Podzamczer D., Pokrovsky V., Pulido F., Almond S., Margolis D., Brennan C., Min S. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. Lancet 2013, 381:735-743. for the SPRING-2 study group.
12. Reese M.J., Savina P.M., Generaux G.T., Tracey H., Humphreys J.E., Kanaoka E., Webster L.O., Harmon K.A., Clarke J.D., Polli J.W. In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor. Drug Metab. Dispos. 2013, 41:353-361.
13. Shiran M.R., Lennard M.S., Iqbal M.Z., Langundoye O., Seivewright N., Tucker G.T., Rostami-Hodjegan A. Contribution of the activities of CYP3A, CYP2D6, CYP1A2 and other potential covariates to the disposition of methadone in patients undergoing methadone maintenance treatment. Br. J. Clin. Pharmacol. 2009, 67:29-37.
14. Song I., Mark S., Borland J., Chen S., Wajima T., Peppercorn A., Piscitelli S. Dolutegravir has no effect on the pharmacokinetics of methadone or oral contraceptives with norgestimate and ethinyl estradiol. Abstract J-102 Presented at the 20th Conference on Retroviruses and Opportunistic Infections 2013, 3-6.
15. Stocker H., Kruse G., Kreckel P., Herzmann C., Arastéh K., Claus J., Jessen H., Cordes C., Hintsche B., Schlote F., Schneider L., Kurowski M. Nevirapine significantly reduces the levels of racemic methadone and (R)-methadone in human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. 2004, 48:4148-4153.
16. Van Heeswijk R., Vandevoorde A., Verboven P., Boogaerts G., De Paepe E., van Solingen-Ristea R., Garg V., Beumont M. The pharmacokinetic interaction between methadone and the investigational HCV protease inhibitor telaprevir. J. Hepatol. 2011, 54(suppl. 1):S491-S492.